Drugs / Fixed neoantigen tumor vaccine
Fixed neoantigen tumor vaccine
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT06496373 | Jul 2024 → Jun 2026 overdue | pancreas disorder | Ruijin Hospital | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Fixed neoantigen tumor vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06496373 ↗ |
| Modality | Messenger RNA (mRNA) | “Single/Fixed neoantigen mRNA vaccine includes pancreatic cancer driver mutations such as KRAS G12D, G12V, G12R, G12C, etc. Each vaccine has one neoantigen encoded by mRNA.” NCT06496373 ↗ |